Skip to content
OpenCapital
Get started

MoonLake Immunotherapeutics MLTX Increase (Decrease) in Prepaid Expense

Increase (Decrease) in Prepaid Expense at other companies

Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
——
Immunovant, Inc. logo
Immunovant, Inc.IMVT
——

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.49B-45.9%
Enterprise value$1.29B-50.0%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidExpense.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's increase (decrease) in prepaid expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MoonLake Immunotherapeutics's increase (decrease) in prepaid expense?
MoonLake Immunotherapeutics (MLTX) reported increase (decrease) in prepaid expense of $10.1M in Q1 2026.
How has MoonLake Immunotherapeutics's increase (decrease) in prepaid expense changed year-over-year?
MoonLake Immunotherapeutics's increase (decrease) in prepaid expense increased by 3799.6% year-over-year, from -$273K to $10.1M.
What is the long-term trend for MoonLake Immunotherapeutics's increase (decrease) in prepaid expense?
Over 2 years (2021 to 2025), MoonLake Immunotherapeutics's increase (decrease) in prepaid expense has grown at a 89.5% compound annual growth rate (CAGR), from -$156.14K to -$561K.